Every 10-Q that uniQure N.V. (QURE) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow QURE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QURE filings page.
uniQure (QURE) filed its Q3 2025 10‑Q, reporting wider losses but a much stronger cash position. Total revenues were $3.7 million, up from $2.3 million a year ago, driven by license revenue. Net loss was $80.5 million, compared to $44.4 million, as R&D and SG&A expenses increased and royalty‑financing interest remained sizable.
Liquidity improved materially: cash and cash equivalents were $597.1 million as of September 30, 2025. The company completed follow‑on offerings in January/February and September, receiving net proceeds of $70.1 million, $10.4 million, and $323.7 million, respectively; September included pre‑funded warrants to purchase 0.5 million shares and a $30.7 million related liability at quarter‑end. Liability from the HEMGENIX royalty financing was $469.1 million.
Debt was refinanced under a Hercules facility maturing October 1, 2030, with $50.0 million drawn and up to $100.0 million more available upon a Biologics License Application (BLA) approval for AMT‑130 prior to June 15, 2027. The company reported positive AMT‑130 Phase I/II topline data; however, following an October pre‑BLA meeting, the FDA feedback indicates the external‑control data may not be adequate as primary evidence, making BLA timing unclear. Ordinary shares outstanding were 62,165,900 as of September 30, 2025.